MacroGenics (MGNX) PT Lowered to $8 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BTIG Downgrades MacroGenics (MGNX) to Neutral
July 31, 2024 4:18 PM EDTBTIG analyst Kaveri Pohlman downgraded MacroGenics (NASDAQ: MGNX) from Buy to Neutral.
The analyst comments "MacroGenics has discontinued the Tamarack study, evaluating vobra duo for mCRPC, after a review of its risk/benefit profile. This decision follows the study's IDMC recommendation to discontinue treatment for the remaining study participants who were eligible to receive additional doses. For reference, the majority... More
